



**a**, **d** Best percent change in the sum of target lesions diameters (longest diameter for non-nodular lesions and short axis for nodal lesions) from baseline in arm C (**a**) and arm E (**d**). Thirty-eight patients in arm C and 38 patients in arm E with postbaseline tumor assessments of target lesions are represented in the figure, while 8 patients in arm C and 8 patients in arm E without postbaseline tumor assessments of target lesions are not shown. The dashed lines at +20% and -30% indicate thresholds for progressive disease and partial response, respectively, according to RECIST v1.1.

**b**, **e** Durability of treatment in arm C (**b**) and arm E (**e**).

**c**, **f** The longitudinal change in the sum of longest target lesions diameters from baseline in arm C (c) and arm E (f) with at least one response assessment.

**Abbreviations:** CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; AE, adverse event.